You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevomethadyl Acetate
Accession NumberDB01227  (APRD00745)
TypeSmall Molecule
GroupsApproved
DescriptionA narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. [PubChem]
Structure
Thumb
Synonyms
(-)-alpha-Acetylmethadol
(1S,4S)-4-(dimethylamino)-1-Ethyl-2,2-diphenylpentyl acetate
1-alpha-Acetylmethadol
LAAM
Levacetilmetadol
Levacetylmethadol
Levacetylmethadolum
Levo-alpha-acetylmethadol
Levo-methadyl acetate
Levo-α-acetylmethadol
Levomethadyl
Levomethadyl acetate
Orlaam
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OrlaamNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Levomethadyl acetate hydrochloride
ThumbNot applicableDBSALT001444
Categories
UNIIR3B637Y991
CAS number1477-40-3
WeightAverage: 353.4977
Monoisotopic: 353.235479241
Chemical FormulaC23H31NO2
InChI KeyInChIKey=XBMIVRRWGCYBTQ-AVRDEDQJSA-N
InChI
InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
IUPAC Name
(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl acetate
SMILES
CC[[email protected]](OC(C)=O)C(C[[email protected]](C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Aralkylamine
  • Acetate salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.
PharmacodynamicsLevomethadyl acetate (also known as LAAM) is a synthetic synthetic opioid analgesic with multiple actions quantitatively similar to those as morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, levomethadyl acetate is more active and more toxic than morphine. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. In this respect, the drug is similar to Methadone and also has structural similarities to it. The levomethadyl acetate abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.
Mechanism of actionOpiate receptors (Mu, Kappa, Delta) are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Levomethadyl acetate effectively opens calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist), resulting in hyperpolarization and reduced neuronal excitability.
Related Articles
AbsorptionLevomethadyl acetate is rapidly absorbed from an oral solution.
Volume of distributionNot Available
Protein bindingApproximately 80%
Metabolism

Levomethadyl acetate undergoes extensive first-pass metabolism to the active demethylated metabolite nor-levomethadyl acetate, which is further demethylated to a second active metabolite, dinor-levomethadyl acetate. These metabolites are more potent than the parent drug.

SubstrateEnzymesProduct
Levomethadyl Acetate
noracymethadolDetails
Levomethadyl Acetate
Nor-levomethadyl acetate (nor-LAAM)Details
Nor-levomethadyl acetate (nor-LAAM)
Dinor-levomethadyl acetateDetails
Route of eliminationNot Available
Half life2.6 days
ClearanceNot Available
ToxicitySigns of overdose include apnea, circulatory collapse, pulmonary edema, cardiac arrest, and death.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Levomethadyl Acetate Action Action PathwayDrug actionSMP00677
Levomethadyl Acetate Metabolism PathwayDrug metabolismSMP00638
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9648
Caco-2 permeable+0.7459
P-glycoprotein substrateSubstrate0.5822
P-glycoprotein inhibitor IInhibitor0.8472
P-glycoprotein inhibitor IINon-inhibitor0.8897
Renal organic cation transporterNon-inhibitor0.6473
CYP450 2C9 substrateNon-substrate0.7976
CYP450 2D6 substrateNon-substrate0.8641
CYP450 3A4 substrateSubstrate0.6658
CYP450 1A2 substrateInhibitor0.5619
CYP450 2C9 inhibitorNon-inhibitor0.8153
CYP450 2D6 inhibitorInhibitor0.7123
CYP450 2C19 inhibitorNon-inhibitor0.7312
CYP450 3A4 inhibitorInhibitor0.5242
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5811
Ames testNon AMES toxic0.9016
CarcinogenicityCarcinogens 0.7025
BiodegradationNot ready biodegradable0.9792
Rat acute toxicity3.3406 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9706
hERG inhibition (predictor II)Inhibitor0.7157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility>15 mg/mLNot Available
logP5.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00179 mg/mLALOGPS
logP4.78ALOGPS
logP4.88ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity117.86 m3·mol-1ChemAxon
Polarizability40.53 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN07BC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Levomethadyl Acetate.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Levomethadyl Acetate.
AcepromazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levomethadyl Acetate.
adipiplonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levomethadyl Acetate.
AlimemazineAlimemazine may increase the hypotensive activities of Levomethadyl Acetate.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomethadyl Acetate.
AlvimopanThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amiloride.
AmiodaroneThe metabolism of Levomethadyl Acetate can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Levomethadyl Acetate which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amobarbital.
AmoxapineLevomethadyl Acetate may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levomethadyl Acetate.
AmperozideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Levomethadyl Acetate.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Levomethadyl Acetate.
AprepitantThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Asenapine.
AtazanavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Levomethadyl Acetate can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levomethadyl Acetate.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Levomethadyl Acetate.
AzaperoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Azaperone.
AzelastineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Levomethadyl Acetate.
AzosemideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Levomethadyl Acetate.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Levomethadyl Acetate.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Levomethadyl Acetate.
BenzphetamineBenzphetamine may increase the analgesic activities of Levomethadyl Acetate.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Levomethadyl Acetate.
BoceprevirThe metabolism of Levomethadyl Acetate can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Levomethadyl Acetate can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
BrimonidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Levomethadyl Acetate.
BuprenorphineBuprenorphine may decrease the analgesic activities of Levomethadyl Acetate.
BuprenorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levomethadyl Acetate.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levomethadyl Acetate.
ButacaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Levomethadyl Acetate.
ButorphanolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butorphanol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levomethadyl Acetate.
CarbinoxamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carisoprodol.
CeritinibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levomethadyl Acetate.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Levomethadyl Acetate.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomethadyl Acetate.
ChlorothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Levomethadyl Acetate.
ChlorphentermineChlorphentermine may increase the analgesic activities of Levomethadyl Acetate.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Levomethadyl Acetate.
ChlorpromazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomethadyl Acetate.
CitalopramLevomethadyl Acetate may increase the serotonergic activities of Citalopram.
ClarithromycinThe metabolism of Levomethadyl Acetate can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Levomethadyl Acetate can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with clomethiazole.
ClomipramineLevomethadyl Acetate may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levomethadyl Acetate.
ClonazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levomethadyl Acetate.
ClotrimazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levomethadyl Acetate.
CobicistatThe metabolism of Levomethadyl Acetate can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levomethadyl Acetate.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levomethadyl Acetate.
ConivaptanThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Conivaptan.
CrizotinibThe metabolism of Levomethadyl Acetate can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomethadyl Acetate.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Levomethadyl Acetate.
CyclosporineThe metabolism of Levomethadyl Acetate can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyproheptadine.
DabrafenibThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Levomethadyl Acetate.
DapoxetineLevomethadyl Acetate may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Levomethadyl Acetate.
DarunavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Levomethadyl Acetate can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomethadyl Acetate.
DesipramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levomethadyl Acetate.
DesmopressinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Detomidine.
DexamethasoneThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Levomethadyl Acetate.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Levomethadyl Acetate.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Levomethadyl Acetate.
DextromoramideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Levomethadyl Acetate.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Levomethadyl Acetate.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levomethadyl Acetate.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levomethadyl Acetate.
DifenoxinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Levomethadyl Acetate can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dihydromorphine.
DiltiazemThe metabolism of Levomethadyl Acetate can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levomethadyl Acetate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levomethadyl Acetate.
DoramectinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Doxepin.
DoxycyclineThe metabolism of Levomethadyl Acetate can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
DoxylamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
DronedaroneThe metabolism of Levomethadyl Acetate can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Levomethadyl Acetate.
DrospirenoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate.
EcgonineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Efonidipine.
EluxadolineLevomethadyl Acetate may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Levomethadyl Acetate.
EntacaponeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Entacapone.
EnzalutamideThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Eplerenone.
ErythromycinThe metabolism of Levomethadyl Acetate can be decreased when combined with Erythromycin.
EscitalopramLevomethadyl Acetate may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levomethadyl Acetate.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomethadyl Acetate.
Etacrynic acidThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etacrynic acid.
EthanolLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Levomethadyl Acetate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Levomethadyl Acetate.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Levomethadyl Acetate.
EthosuximideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomethadyl Acetate.
EtoperidoneLevomethadyl Acetate may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etorphine.
EtravirineThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fencamfamine.
FenfluramineLevomethadyl Acetate may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levomethadyl Acetate.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Levomethadyl Acetate.
FexofenadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flibanserin.
FluconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flunitrazepam.
FluoxetineLevomethadyl Acetate may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levomethadyl Acetate.
FluphenazineFluphenazine may increase the hypotensive activities of Levomethadyl Acetate.
FluphenazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levomethadyl Acetate.
FluspirileneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluticasone Propionate.
FluvoxamineLevomethadyl Acetate may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Levomethadyl Acetate can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Furosemide.
Fusidic AcidThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levomethadyl Acetate.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Levomethadyl Acetate.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Levomethadyl Acetate.
GuanfacineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Levomethadyl Acetate.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levomethadyl Acetate.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Levomethadyl Acetate.
HeroinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Levomethadyl Acetate.
HexobarbitalThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Levomethadyl Acetate.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levomethadyl Acetate.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levomethadyl Acetate.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Levomethadyl Acetate.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
HydroxyzineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Levomethadyl Acetate.
IdelalisibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Iloperidone.
ImatinibThe metabolism of Levomethadyl Acetate can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Imipramine.
IndalpineLevomethadyl Acetate may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Indapamide.
IndinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levomethadyl Acetate.
IsavuconazoniumThe metabolism of Levomethadyl Acetate can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levomethadyl Acetate.
IsosorbideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Isosorbide.
IsradipineThe metabolism of Levomethadyl Acetate can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomethadyl Acetate.
KetazolamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketobemidone.
KetoconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Levomethadyl Acetate.
LevocabastineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Levodopa.
LevomilnacipranLevomethadyl Acetate may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levomethadyl Acetate.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Levomethadyl Acetate.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Levomethadyl Acetate.
LithiumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lofentanil.
LopinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levomethadyl Acetate.
LovastatinThe metabolism of Levomethadyl Acetate can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levomethadyl Acetate.
Lu AA21004Levomethadyl Acetate may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Levomethadyl Acetate.
LuliconazoleThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levomethadyl Acetate.
MeclizineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Levomethadyl Acetate.
MelperoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Levomethadyl Acetate.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomethadyl Acetate.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomethadyl Acetate.
MersalylThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Levomethadyl Acetate.
MesoridazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Levomethadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Levomethadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Levomethadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomethadyl Acetate.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Levomethadyl Acetate.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Levomethadyl Acetate.
MethsuximideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Levomethadyl Acetate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Levomethadyl Acetate.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Levomethadyl Acetate.
MetolazoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone.
MetyrosineLevomethadyl Acetate may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levomethadyl Acetate.
MifepristoneThe metabolism of Levomethadyl Acetate can be decreased when combined with Mifepristone.
MilnacipranLevomethadyl Acetate may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
MirtazapineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levomethadyl Acetate.
MitotaneThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Levomethadyl Acetate.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Levomethadyl Acetate.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Levomethadyl Acetate.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.
NabiloneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nabilone.
NafcillinThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Levomethadyl Acetate.
NalbuphineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Levomethadyl Acetate can be decreased when used in combination with Naltrexone.
NefazodoneThe metabolism of Levomethadyl Acetate can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Levomethadyl Acetate can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Levomethadyl Acetate can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Levomethadyl Acetate.
OlanzapineLevomethadyl Acetate may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate.
OlaparibThe metabolism of Levomethadyl Acetate can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Levomethadyl Acetate.
OpiumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Opium.
OrphenadrineLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Levomethadyl Acetate.
OsanetantThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Osanetant.
OsimertinibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomethadyl Acetate.
OxprenololThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Levomethadyl Acetate.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Levomethadyl Acetate.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levomethadyl Acetate.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levomethadyl Acetate.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Levomethadyl Acetate.
PalbociclibThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levomethadyl Acetate.
ParaldehydeLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Levomethadyl Acetate.
ParoxetineLevomethadyl Acetate may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levomethadyl Acetate.
PentazocinePentazocine may decrease the analgesic activities of Levomethadyl Acetate.
PentazocineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levomethadyl Acetate.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Levomethadyl Acetate.
PerampanelThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Levomethadyl Acetate.
PerphenazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levomethadyl Acetate.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levomethadyl Acetate.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Levomethadyl Acetate.
PhenytoinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Levomethadyl Acetate.
PipamperoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Levomethadyl Acetate.
PipotiazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levomethadyl Acetate.
PiretanideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pomalidomide.
PosaconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium Citrate.
PramipexoleLevomethadyl Acetate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Levomethadyl Acetate.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Levomethadyl Acetate.
PrimidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Levomethadyl Acetate.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Levomethadyl Acetate.
ProchlorperazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Levomethadyl Acetate.
PromazinePromazine may increase the hypotensive activities of Levomethadyl Acetate.
PromazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Levomethadyl Acetate.
PromethazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Levomethadyl Acetate.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Levomethadyl Acetate.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levomethadyl Acetate.
PropoxycaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomethadyl Acetate.
QuinethazoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Levomethadyl Acetate.
RamelteonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ramelteon.
RamosetronLevomethadyl Acetate may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Levomethadyl Acetate can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levomethadyl Acetate.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Levomethadyl Acetate.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levomethadyl Acetate.
RifabutinThe metabolism of Levomethadyl Acetate can be increased when combined with Rifabutin.
RifampicinThe metabolism of Levomethadyl Acetate can be increased when combined with Rifampicin.
RifapentineThe metabolism of Levomethadyl Acetate can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levomethadyl Acetate.
RitonavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Romifidine.
RopiniroleLevomethadyl Acetate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomethadyl Acetate.
RotigotineLevomethadyl Acetate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levomethadyl Acetate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Levomethadyl Acetate can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levomethadyl Acetate.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levomethadyl Acetate.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levomethadyl Acetate.
SertindoleThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sertindole.
SertralineLevomethadyl Acetate may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sevoflurane.
SildenafilThe metabolism of Levomethadyl Acetate can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Levomethadyl Acetate.
SpironolactoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Spironolactone.
St. John's WortThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Levomethadyl Acetate.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate.
SulfisoxazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Levomethadyl Acetate.
SuvorexantThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tasimelteon.
TelaprevirThe metabolism of Levomethadyl Acetate can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Levomethadyl Acetate can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levomethadyl Acetate.
TetrabenazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrodotoxin.
ThalidomideLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Levomethadyl Acetate.
TheobromineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomethadyl Acetate.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Levomethadyl Acetate.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Levomethadyl Acetate.
ThioridazineThioridazine may increase the hypotensive activities of Levomethadyl Acetate.
ThioridazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiagabine.
TiclopidineThe metabolism of Levomethadyl Acetate can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Levomethadyl Acetate.
TizanidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tizanidine.
TocilizumabThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Levomethadyl Acetate.
TolvaptanThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levomethadyl Acetate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levomethadyl Acetate.
TrazodoneLevomethadyl Acetate may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomethadyl Acetate.
TriamtereneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levomethadyl Acetate.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Levomethadyl Acetate.
TrifluoperazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Levomethadyl Acetate.
TriflupromazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Levomethadyl Acetate.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Levomethadyl Acetate.
TrimipramineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Levomethadyl Acetate.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Levomethadyl Acetate.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Levomethadyl Acetate.
UlaritideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Levomethadyl Acetate.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Levomethadyl Acetate.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levomethadyl Acetate.
VenlafaxineThe metabolism of Levomethadyl Acetate can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Levomethadyl Acetate can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Vigabatrin.
VilazodoneLevomethadyl Acetate may increase the serotonergic activities of Vilazodone.
VoriconazoleThe metabolism of Levomethadyl Acetate can be decreased when combined with Voriconazole.
VortioxetineLevomethadyl Acetate may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levomethadyl Acetate.
XylazineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomethadyl Acetate.
ZiconotideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ziconotide.
ZimelidineLevomethadyl Acetate may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe metabolism of Levomethadyl Acetate can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Levomethadyl Acetate.
ZonisamideThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levomethadyl Acetate.
ZotepineThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB: Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem. 1997 Nov 14;272(46):28869-74. [PubMed:9360954 ]
  2. Skoulis NP, James RC, Harbison RD, Roberts SM: Depression of hepatic glutathione by opioid analgesic drugs in mice. Toxicol Appl Pharmacol. 1989 Jun 1;99(1):139-47. [PubMed:2471291 ]
  3. Kreek MJ: Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216. [PubMed:10911931 ]
  4. Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71. [PubMed:11561100 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNB4
Uniprot ID:
P30926
Molecular Weight:
56378.985 Da
References
  1. Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71. [PubMed:11561100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA3
Uniprot ID:
P32297
Molecular Weight:
57479.54 Da
References
  1. Xiao Y, Smith RD, Caruso FS, Kellar KJ: Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther. 2001 Oct;299(1):366-71. [PubMed:11561100 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Oda Y, Kharasch ED: Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001 Sep;298(3):1021-32. [PubMed:11504799 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23